Sodium Pyruvate-1-¹³C: Research Guide & Lab Protocol

Sodium pyruvate-1-¹³C is a stable-isotope-labeled form of the key glycolytic intermediate pyruvate, in which the C-1 carbonyl carbon is enriched with carbon-13, enabling precise tracing of pyruvate metabolism through the TCA cycle, gluconeogenesis, and related pathways using NMR, MS, or hyperpolarized MRI techniques.

Chemical Name

Sodium pyruvate-1-¹³C (sodium 2-oxo[1-¹³C]propanoate)

SKU / Catalog Number

S345696

Isotopic Label Position

C-1 carbonyl carbon enriched with ¹³C

Isotope

Carbon-13 (¹³C), stable, non-radioactive

Primary Applications

Metabolic flux analysis, ¹³C NMR spectroscopy, hyperpolarized MRI, isotope tracer studies

Storage Recommendation

Store at −20 °C, desiccated, protected from light and moisture

Product Overview and Chemical Properties

Sodium pyruvate-1-¹³C (Aladdin SKU S345696) is the sodium salt of pyruvic acid selectively labeled with the stable isotope carbon-13 at the C-1 (carbonyl) position. Pyruvate occupies a central node in intermediary metabolism, serving as the terminal product of glycolysis and a direct precursor for the tricarboxylic acid (TCA) cycle, gluconeogenesis, amino acid biosynthesis, and lipid synthesis. The ¹³C label at C-1 is strategically positioned because this carbon is released as ¹³CO₂ upon oxidative decarboxylation by pyruvate dehydrogenase (PDH), providing a direct and highly specific readout of PDH flux.

The compound is water-soluble, chemically identical to unlabeled sodium pyruvate in all biological and physicochemical respects, and is non-radioactive, allowing safe handling under standard laboratory conditions without specialist radiation licenses. The ¹³C nucleus is NMR-active (spin I = 1/2) and is detectable by both solution-state ¹³C NMR and by mass spectrometry (MS)-based isotopologue analysis, making this reagent compatible with a broad range of analytical platforms.

Key Applications in Metabolic Research

1. Metabolic Flux Analysis (MFA) and ¹³C-MFA: Sodium pyruvate-1-¹³C is widely employed as a tracer substrate in isotope-assisted metabolic flux analysis. By introducing the labeled compound into cell culture medium or perfused tissues and measuring downstream ¹³C label incorporation into metabolites by GC-MS or LC-MS, researchers can calculate absolute fluxes through the TCA cycle, anaplerotic pathways, and biosynthetic branches. The C-1 label yields characteristic isotopologue patterns that distinguish PDH-mediated entry into the TCA cycle from alternative routes.

2. Hyperpolarized ¹³C MRI: The C-1 carbonyl of pyruvate is the preferred labeling site for dynamic nuclear polarization (DNP)-based hyperpolarized ¹³C MRI experiments in vivo. When dissolved-phase DNP is applied, the ¹³C signal is transiently enhanced by four to five orders of magnitude, enabling real-time imaging of pyruvate-to-lactate conversion (via LDH), pyruvate-to-bicarbonate conversion (via PDH + carbonic anhydrase), and pyruvate-to-alanine conversion (via ALT). This technique has significant translational implications for non-invasive metabolic imaging in oncology and cardiology.

3. ¹³C NMR Spectroscopy: The enhanced natural abundance of ¹³C at C-1 greatly increases sensitivity for detecting the labeled resonance and its labeled metabolic descendants in solution-state NMR experiments. This allows direct, non-destructive monitoring of metabolic conversions in cell extracts or intact perfused organs.

4. Enzyme Mechanism and Kinetics Studies: The site-specific label enables mechanistic investigations of pyruvate-metabolizing enzymes, including pyruvate carboxylase (PC), pyruvate kinase (PK), and lactate dehydrogenase (LDH), by tracking the fate of C-1 through isotope-sensitive NMR or MS readouts.

Solution Preparation and Handling Protocol

Stock Solution Preparation:

1. Allow the vial to equilibrate to room temperature in a sealed desiccator before opening to minimize condensation and moisture absorption.
2. Weigh the required mass using an analytical balance. For a 100 mM stock solution, dissolve the appropriate quantity in sterile, nuclease-free water (or the appropriate buffer, e.g., phosphate-buffered saline, pH 7.4). Sodium pyruvate-1-¹³C is freely soluble in water at physiological pH.
3. Filter-sterilize through a 0.22 µm membrane filter if the solution is intended for cell culture applications.
4. Dispense into single-use aliquots to minimize freeze-thaw cycles, which can cause gradual chemical degradation of pyruvate (spontaneous decarboxylation or hydration to form pyruvate hydrate).

Storage: Store the dry powder at −20 °C in a tightly sealed container with desiccant, protected from light. Prepared aqueous solutions should be used promptly; if storage is necessary, keep at −80 °C for short-term use (recommend use within 1–2 weeks). Avoid repeated freeze-thaw cycles.

Quality Check: Prior to use in quantitative tracer experiments, confirm isotopic enrichment using ¹³C NMR or high-resolution MS to verify that the ¹³C enrichment at C-1 meets the stated specification. Record the lot number for experimental traceability.

Safety: Sodium pyruvate-1-¹³C is not classified as hazardous under standard laboratory chemical regulations. Handle using standard good laboratory practice (GLP): wear nitrile gloves, lab coat, and eye protection. Consult the Safety Data Sheet (SDS) for full hazard and disposal information.

Experimental Design Considerations for Tracer Studies

Isotopic Steady State: For quantitative ¹³C-MFA, cells or tissues should be incubated with Sodium pyruvate-1-¹³C until isotopic steady state is achieved, typically requiring 3–6 doubling times for cultured cells. Verify steady state by confirming that isotopologue distributions in key metabolites (e.g., citrate, malate, aspartate) are constant over sequential sampling time points.

Tracer Concentration: Use physiologically relevant pyruvate concentrations where possible. Common cell culture concentrations range from 0.5 mM to 5 mM. Avoid supraphysiological concentrations that may perturb metabolic phenotype or cause oxidative stress.

Mixing with Unlabeled Pyruvate: When using partially labeled tracers for specific experimental designs (e.g., [1-¹³C] mixed with [U-¹³C₃] or natural abundance pyruvate), clearly document the molar fraction of each isotopologue to facilitate accurate computational modeling.

Downstream Analysis: For MS-based analysis, quench metabolism rapidly (e.g., liquid nitrogen or cold methanol/water extraction). For NMR-based analysis, prepare cell extracts using standard dual-phase extraction protocols and use an internal standard for quantification. Correct all measured isotopologue distributions for natural abundance of ¹³C using appropriate correction software or algorithms.

Controls: Include parallel cultures with natural abundance (unlabeled) sodium pyruvate as a background control, and where applicable, compare with [U-¹³C₃]-pyruvate to resolve ambiguous labeling patterns.

Troubleshooting Common Issues

Low or No ¹³C Signal Detected by NMR/MS: Verify isotopic enrichment of the stock solution before use by independent ¹³C NMR or HRMS analysis. Confirm that tracer concentration in the experimental system is sufficient for the detection limits of your instrument. Check for inadvertent dilution with unlabeled pyruvate (e.g., from media supplements).

Rapid Disappearance of Pyruvate from Medium: Pyruvate is rapidly consumed by cells and can also spontaneously decarboxylate in warm aqueous solution, particularly above pH 7.4 or at elevated temperatures. Freshly prepare tracer solutions and add to pre-equilibrated culture medium immediately before the experiment. Monitor pyruvate concentration in medium over time if flux calculations require accurate extracellular concentration data.

Unexpected Isotopologue Patterns: Background ¹³C incorporation from CO₂ in incubator air or from isotopically labeled components of commercial media can confound results. Perform natural abundance correction. Evaluate all media components for hidden sources of unlabeled or partially labeled carbon.

Degradation of Stored Solutions: If MS analysis reveals unexpected peaks corresponding to pyruvate hydrate or acetaldehyde (products of pyruvate decomposition), discard the solution and prepare fresh stock. Always store solutions at −80 °C and limit freeze-thaw cycles to one.

Frequently asked questions

What makes the C-1 position the preferred labeling site in pyruvate for metabolic studies?

The C-1 carbonyl carbon of pyruvate is selectively released as CO₂ during oxidative decarboxylation catalyzed by pyruvate dehydrogenase (PDH), making ¹³C at this position a direct and specific reporter of PDH activity. This distinguishes PDH-mediated TCA cycle entry from other pyruvate-consuming reactions and is also the basis of hyperpolarized ¹³C MRI experiments, where ¹³CO₂ and H¹³CO₃⁻ signals are used to image PDH flux in vivo in real time.

Is Sodium pyruvate-1-¹³C safe to use without a radioactive materials license?

Yes. Carbon-13 is a stable, non-radioactive isotope and poses no radiation hazard. Sodium pyruvate-1-¹³C can be handled under standard laboratory conditions following normal good laboratory practice (GLP) guidelines without any radioactive material license or specialist containment. Standard chemical safety precautions (gloves, lab coat, eye protection) are sufficient; consult the SDS for full details.

How should I validate the isotopic enrichment of Sodium pyruvate-1-¹³C before use in quantitative experiments?

Isotopic enrichment at C-1 can be confirmed by solution-state ¹³C NMR spectroscopy, where the C-1 resonance of the labeled compound will show dramatically enhanced intensity relative to natural abundance. Alternatively, high-resolution mass spectrometry (HRMS) can be used to measure the M+1 isotopologue fraction and verify that ¹³C enrichment meets the certificate of analysis specification. Always record the lot number and enrichment data in your experimental records.

Can Sodium pyruvate-1-¹³C be used in animal or in vivo studies?

Yes, sodium pyruvate is a naturally occurring, endogenous metabolite with a well-established safety profile, and its ¹³C-labeled form is used in in vivo metabolic flux studies and, in particular, in hyperpolarized ¹³C MRI in preclinical animal models. For in vivo use, ensure the formulation is sterile, pyrogen-free, and prepared to the appropriate pH and concentration. Consult your institutional animal ethics committee and follow all applicable regulations.

What is the difference between Sodium pyruvate-1-¹³C and [U-¹³C₃]-sodium pyruvate?

Sodium pyruvate-1-¹³C carries the ¹³C label exclusively at the C-1 carbonyl carbon, allowing selective tracking of reactions that involve C-1, such as PDH-mediated decarboxylation to ¹³CO₂. [U-¹³C₃]-sodium pyruvate is uniformly labeled at all three carbons (C-1, C-2, and C-3), generating fully labeled acetyl-CoA (¹³C₂) upon PDH action and allowing comprehensive tracing of all three carbons through the TCA cycle. The choice of tracer depends on the specific metabolic question: [1-¹³C] is optimal for PDH flux and hyperpolarized MRI, while [U-¹³C₃] provides broader isotopologue coverage for global flux analysis.

References

1. Ardenkjaer-Larsen JH, et al. Increase in signal-to-noise ratio of >10,000 times in liquid-state NMR. Proc Natl Acad Sci USA. 2003;100(18):10158–10163. doi:10.1073/pnas.1733835100
2. Metabolic flux analysis: a comprehensive review of methodology and its application in disease research. (General textbook-level reference; specific citation to be confirmed.)
3. Merritt ME, et al. Hyperpolarized ¹³C allows a direct measure of flux through a single enzyme-catalyzed step by NMR. Proc Natl Acad Sci USA. 2007;104(50):19773–19777. doi:10.1073/pnas.0706235104
4. Antoniewicz MR. Methods and advances in metabolic flux analysis: a mini-review. J Ind Microbiol Biotechnol. 2015;42(3):317–325. doi:10.1007/s10295-015-1585-x

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.